Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Clinical trial NCT02869633 · COMPLETED

Trial details

NCT number: NCT02869633
Sponsor: Vanderbilt-Ingram Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Blastoid Variant Mantle Cell Lymphoma Recurrent Chronic Lymphocytic Leukemia Recurrent Follicular Lymphoma Recurrent Hodgkin Lymphoma Recurrent Mantle Cell Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Follicular Lymphoma Refractory Hodgkin Lymphoma Refractory Mantle Cell Lymphoma

Start date: 2016-11-01
Primary completion: 2021-11-18
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.